Vivy Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vivy Tran has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Jenny S. Sauk
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
2 shared publications Aileen Tlamsa
Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA
1 shared publication- Ana Acuna-Villaorduna
Division of Hematology, Department of Oncology, Albert Einstein College of Medicine, Bronx, NY, USA
1 shared publication Andrew T Weber
General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, CA
1 shared publicationBenjamin Nulsen
Vatche and Tamar Manoukian Division of Digestive Diseases, University of California Los Angeles, Los Angeles, California
1 shared publicationBerkeley N. Limketkai
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
1 shared publication
Latest Publications
- 27 November 2019
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 21 (11) , 60
IBD in the Elderly: Management Challenges and Therapeutic Considerations
Elderly patients with inflammatory bowel disease (IBD) are increasing in prevalence as our population ages and the incidence of IBD increases. The purpose of this review is to describe the management challenges in elderly IBD patients, including comorbid conditions and therapeutic considerations unique to the elderly population.
- 27 November 2019
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 21 (11) , 60
IBD in the Elderly: Management Challenges and Therapeutic Considerations
Elderly patients with inflammatory bowel disease (IBD) are increasing in prevalence as our population ages and the incidence of IBD increases. The purpose of this review is to describe the management challenges in elderly IBD patients, including comorbid conditions and therapeutic considerations unique to the elderly population.
- Open Access
- 1 May 2019
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 1 (1)
Higher Sedation Requirements Among Inflammatory Bowel Disease Patients Undergoing Colonoscopy for Disease Activity Assessment or Dysplasia Surveillance
Background and Aims: Patients with inflammatory bowel disease (IBD) require colonoscopy for diagnosis, disease activity assessment, and dysplasia surveillance. Few studies have evaluated anesthesia needs of IBD patients during procedures. This study aimed to examine sedation requirements of IBD patients undergoing colonoscopy. Methods: A retrospective cohort study of IBD and non-IBD patients presenting for colonoscopy between August 2015 and December 2016 was undertaken. Data collected included patient and procedure focused variables. Sedation was categorized as intravenous conscious sedation (IVCS) or monitored anesthesia care (MAC). Results: A total of: 522 consecutive colonoscopies (212 IBD, 310 non-IBD) between August 2015 and December 2016 met criteria for inclusion. In total, 323 cases utilized IVCS (56 IBD, 267 non-IBD) and 196 used MAC (155 IBD, 41 non-IBD). Compared with non-IBD patients (13.2%), more IBD patients (73.1%) required MAC (P < 0.01). For IVCS cases, IBD patients required more midazolam (5.73 mg versus non-IBD 4.31 mg; P <0.01) and opioid (IBD 157.59 µg fentanyl equivalents versus non-IBD 119.41 µg; P < 0.01). Diphenhydramine was more frequently added to IVCS for IBD cases (IBD 25.0% versus non-IBD 1.9%; P < 0.01). For MAC cases, propofol dosage was not significantly different between groups (IBD 355.64 mg versus non-IBD 317.104 mg; P = 0.29). IBD colonoscopies took longer (IBD 22.7 versus non-IBD 17.2 min; P < 0.01) and more patients had recent narcotic use (IBD 21.2% versus non-IBD 9.0%; P < 0.01). Conclusions: IBD patients required more IVCS, including greater diphenhydramine use with longer procedure times compared with non-IBD patients. These findings suggest MAC should be considered for IBD procedural sedation.
- 1 May 2019
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 1 (1)
Open AccessHigher Sedation Requirements Among Inflammatory Bowel Disease Patients Undergoing Colonoscopy for Disease Activity Assessment or Dysplasia Surveillance
Background and Aims: Patients with inflammatory bowel disease (IBD) require colonoscopy for diagnosis, disease activity assessment, and dysplasia surveillance. Few studies have evaluated anesthesia needs of IBD patients during procedures. This study aimed to examine sedation requirements of IBD patients undergoing colonoscopy. Methods: A retrospective cohort study of IBD and non-IBD patients presenting for colonoscopy between August 2015 and December 2016 was undertaken. Data collected included patient and procedure focused variables. Sedation was categorized as intravenous conscious sedation (IVCS) or monitored anesthesia care (MAC). Results: A total of: 522 consecutive colonoscopies (212 IBD, 310 non-IBD) between August 2015 and December 2016 met criteria for inclusion. In total, 323 cases utilized IVCS (56 IBD, 267 non-IBD) and 196 used MAC (155 IBD, 41 non-IBD). Compared with non-IBD patients (13.2%), more IBD patients (73.1%) required MAC (P < 0.01). For IVCS cases, IBD patients required more midazolam (5.73 mg versus non-IBD 4.31 mg; P <0.01) and opioid (IBD 157.59 µg fentanyl equivalents versus non-IBD 119.41 µg; P < 0.01). Diphenhydramine was more frequently added to IVCS for IBD cases (IBD 25.0% versus non-IBD 1.9%; P < 0.01). For MAC cases, propofol dosage was not significantly different between groups (IBD 355.64 mg versus non-IBD 317.104 mg; P = 0.29). IBD colonoscopies took longer (IBD 22.7 versus non-IBD 17.2 min; P < 0.01) and more patients had recent narcotic use (IBD 21.2% versus non-IBD 9.0%; P < 0.01). Conclusions: IBD patients required more IVCS, including greater diphenhydramine use with longer procedure times compared with non-IBD patients. These findings suggest MAC should be considered for IBD procedural sedation.
- Open Access
- 1 May 2019
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. ume 12, 179-191
Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy
The etiology of ulcerative colitis (UC) is complex and involves a host of genetic, epigenetic and environmental factors. Over the last thirty years, signaling pathways like the Janus kinase (JAK) signaling pathway have been implicated in its pathogenesis. Pharmacologic blockade of this pathway is available through several small molecule inhibitors, including tofacitinib. Tofacitinib is an orally administered pan-JAK inhibitor that was first approved by the Food and Drug Administration (FDA) for use in rheumatologic disorders such as rheumatoid arthritis and psoriatic arthritis. The FDA approved its use in moderate-to-severe active ulcerative colitis in 2018. The aim of this review will be to discuss the role of tofacitinib in ulcerative colitis. We will discuss the role of JAK-STAT signaling, clinical data available for tofacitinib, and the safety profile for this therapy. Tofacitinib’s place in the UC management algorithm is currently being debated. This effective oral therapy is poised to be a mainstay of UC therapeutics. This review will highlight the key clinical features and detail the UC experience to date.
- 1 May 2019
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. ume 12, 179-191
Open AccessEvaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy
The etiology of ulcerative colitis (UC) is complex and involves a host of genetic, epigenetic and environmental factors. Over the last thirty years, signaling pathways like the Janus kinase (JAK) signaling pathway have been implicated in its pathogenesis. Pharmacologic blockade of this pathway is available through several small molecule inhibitors, including tofacitinib. Tofacitinib is an orally administered pan-JAK inhibitor that was first approved by the Food and Drug Administration (FDA) for use in rheumatologic disorders such as rheumatoid arthritis and psoriatic arthritis. The FDA approved its use in moderate-to-severe active ulcerative colitis in 2018. The aim of this review will be to discuss the role of tofacitinib in ulcerative colitis. We will discuss the role of JAK-STAT signaling, clinical data available for tofacitinib, and the safety profile for this therapy. Tofacitinib’s place in the UC management algorithm is currently being debated. This effective oral therapy is poised to be a mainstay of UC therapeutics. This review will highlight the key clinical features and detail the UC experience to date.
- 1 February 2019
- Published by Elsevier in Thrombosis Research
- Vol. 174, 137-140
Natural history and clinical outcomes in patients with portal vein thrombosis by etiology: A retrospective cohort study
- 1 February 2019
- Published by Elsevier in Thrombosis Research
- Vol. 174, 137-140
Natural history and clinical outcomes in patients with portal vein thrombosis by etiology: A retrospective cohort study
- Open Access
- 1 January 2018
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 5 (12) , e971-4
Severe Ileocolonic Crohnʼs Disease Flare Associated with Fecal Microbiota Transplantation Requiring Diverting Ileostomy
Patients with inflammatory bowel disease (IBD) are at increased risk of developing Clostridium difficile infection (CDI). Fecal microbiota transplantation (FMT) is an effective therapy with a high success rate in preventing recurrent CDI. However, patients with IBD have decreased response to FMT for recurrent CDI, with several reports also suggesting potential IBD flare post-FMT. We present a case of mild ileocolonic Crohn's disease in a patient treated with FMT for recurrent CDI who subsequently developed severe steroid-refractory flare requiring surgical intervention 1 week post-FMT. Greater understanding of risk factors associated with post-FMT IBD flare is indicated.
- 1 January 2018
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 5 (12) , e971-4
Open AccessSevere Ileocolonic Crohnʼs Disease Flare Associated with Fecal Microbiota Transplantation Requiring Diverting Ileostomy
Patients with inflammatory bowel disease (IBD) are at increased risk of developing Clostridium difficile infection (CDI). Fecal microbiota transplantation (FMT) is an effective therapy with a high success rate in preventing recurrent CDI. However, patients with IBD have decreased response to FMT for recurrent CDI, with several reports also suggesting potential IBD flare post-FMT. We present a case of mild ileocolonic Crohn's disease in a patient treated with FMT for recurrent CDI who subsequently developed severe steroid-refractory flare requiring surgical intervention 1 week post-FMT. Greater understanding of risk factors associated with post-FMT IBD flare is indicated.
- Open Access
- 1 October 2017
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 63, 1-6
Rapidly growing Mycobacterium infections after cosmetic surgery in medical tourists: the Bronx experience and a review of the literature
- 1 October 2017
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 63, 1-6
Open AccessRapidly growing Mycobacterium infections after cosmetic surgery in medical tourists: the Bronx experience and a review of the literature